Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00566241 · ClinicalTrials.gov registry record · Phase 1
IGF-1 Therapy in Patients With Cystic Fibrosis
A Phase 1 study, sponsored by Stony Brook University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00566241 is a Phase 1 study that was terminated before completion, run by Stony Brook University. The registered enrollment target is 15 participants.
The verdict
NCT00566241, a Phase 1 study, was terminated before completion, sponsored by Stony Brook University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
28 week pilot study to examine the efficacy of recombinant human IGF-1 on body weight and composition in adults with cystic fibrosis.
Interventions
- DRUG Placebo
- DRUG recombinant human IGF-1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-06 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00566241
The ClinicalTrials.gov registry entry for NCT00566241 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stony Brook University, which has 127 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00566241 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00566241 about?
NCT00566241 is a clinical study titled "IGF-1 Therapy in Patients With Cystic Fibrosis". 28 week pilot study to examine the efficacy of recombinant human IGF-1 on body weight and composition in adults with cystic fibrosis.
What is the current status of trial NCT00566241?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2008-06. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00566241?
The interventions under investigation include: Placebo (DRUG), recombinant human IGF-1 (DRUG).
Who is sponsoring clinical trial NCT00566241?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.